Jed Black Selected Research

Sodium Oxybate (gamma Hydroxybutyrate)

1/2022	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
1/2022	Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
1/2022	Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
1/2022	Validation of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years.
1/2022	Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
3/2021	The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017.
1/2021	Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves 1-4).
1/2020	Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
1/2018	Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
12/2017	Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jed Black Research Topics

Disease

37	Narcolepsy 01/2022 - 10/2002
15	Cataplexy 01/2022 - 10/2002
15	Sleepiness 01/2022 - 11/2004
15	Disorders of Excessive Somnolence (Hypersomnia) 01/2022 - 10/2002
10	Obstructive Sleep Apnea 01/2022 - 10/2002
7	Sleep Initiation and Maintenance Disorders (Insomnia) 08/2017 - 10/2002
5	Nausea 01/2019 - 05/2006
5	Headache (Headaches) 01/2019 - 05/2006
4	Sleep Apnea Syndromes (Sleep Apnea) 01/2019 - 01/2003
3	Nasopharyngitis 01/2019 - 01/2018
2	Muscle Weakness 01/2022 - 09/2005
2	Idiopathic Hypersomnia 01/2022 - 01/2022
2	Sleep Wake Disorders 01/2022 - 10/2002
2	Dizziness (Lightheadedness) 01/2018 - 05/2006
1	Enuresis 01/2018
1	Vomiting 01/2018
1	Psychotic Disorders (Schizoaffective Disorder) 01/2018
1	Diarrhea 07/2016
1	Airway Obstruction (Choking) 02/2013
1	Apnea 10/2008
1	Bradycardia 01/2007
1	Syncope (Fainting) 01/2007
1	Body Weight (Weight, Body) 05/2006
1	Fatigue 05/2006
1	Mood Disorders (Mood Disorder) 05/2006
1	Migraine Disorders (Migraine) 05/2006
1	Duodenal Ulcer (Curling's Ulcer) 05/2006
1	Ulcerative Colitis 05/2006
1	Fibromyalgia (Fibrositis) 01/2006
1	Sleep Deprivation 09/2005
1	Parkinson Disease (Parkinson's Disease) 10/2002
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 10/2002
1	Restless Legs Syndrome (Restless Legs) 10/2002
1	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 10/2002
1	Nervous System Diseases (Neurological Disorders) 10/2002

Drug/Important Bio-Agent (IBA)

24	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 01/2022 - 11/2004
10	solriamfetolIBA 01/2022 - 07/2016
8	Modafinil (Provigil)FDA Link 01/2020 - 01/2003
5	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020 - 02/2017
5	OrexinsIBA 08/2017 - 10/2002
4	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 01/2019
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2006
3	SolutionsIBA 01/2022 - 01/2018
2	NexusIBA 01/2021 - 01/2021
2	almorexantIBA 08/2017 - 02/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 02/2017
1	Orexin Receptor AntagonistsIBA 02/2017
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 02/2017
1	BenzodiazepinesIBA 02/2017
1	Hypnotics and Sedatives (Sedatives)IBA 02/2017
1	Anti-Anxiety Agents (Anxiolytics)IBA 02/2017
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 02/2017
1	Oxygen (Dioxygen)IBA 10/2008
1	indiplonIBA 06/2007
1	Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone (FCCP)IBA 02/2007
1	HLA-DQ Antigens (HLA-DQ)IBA 10/2002
1	Psychotropic Drugs (Psychoactive Drugs)IBA 10/2002
1	HLA-DQB1 antigen (HLA DQB1)IBA 10/2002
1	Biological ProductsIBA 10/2002

Therapy/Procedure

10	Therapeutics 01/2022 - 12/2002
3	Continuous Positive Airway Pressure 09/2013 - 05/2006
1	Oral Administration 02/2017
1	Plasmapheresis 09/2005